VRTX
Vertex Pharmaceuticals Incorporated
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+17/100
Last price
505.54
▲ 2.04 (0.41%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
503.46
Prev close
503.50
Day high
507.41
Day low
496.33
Volume
775.06K
Market cap
$127.32B
P/E (TTM)
29.26
52W range
402.58 – 560.25
Day trading desk
Gap from prior close
-0.01%
Prior close 503.50
VWAP
501.55
+0.80% from price
Relative volume
1.01×
Normal
Session range
2.23%
496.33 – 507.41
Position in range
83%
Near session high
ATR (14D)
11.85
2.34% of price
Prior day high
506.01
PDH
Prior day low
496.15
PDL
Bid / ask spread
—
Quote not published
Session volume
1.19M
Avg 1.18M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.64%
-6.6%
1M
-8.02%
-9.2%
3M
+0.78%
-3.7%
6M
+16.31%
-1.9%
YTD
+10.80%
-3.5%
1Y
+24.55%
+8.1%
3Y
+44.45%
-37.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on VRTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+15.60K
Net buying
Buy transactions
10
39.49K shares
Sell transactions
14
23.89K shares
Net transactions
+24
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
537.34K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 28, 26 | AMBROSE KRISTEN Officer |
STOCK | 5.00K | $0 | Direct |
| Aug 27, 26 | SACHS BRUCE I Director |
STOCK | 6.00K | $0 | Direct |
| Jul 21, 26 | TATSIS OURANIA Officer |
STOCK | 8.25K | $0 | Direct |
| Jul 21, 26 | SACHDEV AMIT Officer |
STOCK | 8.25K | $0 | Direct |
| Jul 2, 26 | MCKECHNIE DUNCAN J. Officer |
SELL | 1.54K | $799.78K | Direct |
| Jul 2, 26 | TATSIS OURANIA Officer |
SELL | 1.50K | $787.49K | Direct |
| Jul 1, 26 | LIU JOY Officer |
SELL | 828 | $416.24K | Direct |
| Jun 26, 26 | BOZIC CARMEN Officer |
SELL | 596 | $287.57K | Direct |
| Jun 18, 26 | BOZIC CARMEN Officer |
SELL | 1.02K | $471.41K | Direct |
| Jun 15, 26 | BOZIC CARMEN Officer |
SELL | 4.06K | $1.83M | Direct |
| Jun 5, 26 | BOZIC CARMEN Officer |
SELL | 1.75K | $785.25K | Direct |
| Jun 1, 26 | LIU JOY Officer |
SELL | 828 | $364.25K | Direct |
| May 29, 26 | BOZIC CARMEN Officer |
SELL | 1.97K | $888.30K | Direct |
| May 15, 26 | BUNNAGE MARK E. Officer |
SELL | 33 | $14.96K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALTSHULER DAVID |
Officer | 34.48K | Stock Award(Grant) |
ARBUCKLE STUART A |
Chief Operating Officer | 100.75K | Stock Award(Grant) |
ATKINSON EDWARD MORROW III |
Chief Technology Officer | 18.43K | Sale |
KEWALRAMANI RESHMA |
Chief Executive Officer | 98.28K | Sale |
LEIDEN JEFFREY M |
Officer and Director | 38.78K | Stock Award(Grant) |
LIU JOY |
Officer | 19.13K | Sale |
SACHDEV AMIT |
Officer | 74.03K | Stock Award(Grant) |
SACHS BRUCE I |
Director | 45.00K | Purchase |
TATSIS OURANIA |
Officer | 53.57K | Stock Award(Grant) |
WAGNER CHARLES F JR |
Chief Operating Officer | 48.79K | Stock Award(Grant) |
Fundamentals
Market cap$127.32B
Enterprise value$121.44B
Revenue (TTM)$12.59B
Gross profit$6.92B
EBITDA$5.10B
Net income$4.41B
EPS (TTM)$17.17
Free cash flow$2.63B
Total cash$7.85B
Total debt$1.98B
Book value / share$79.92
Shares outstanding253.46M
Float252.69M
Short % of float2.10%
Dividend yield0.00%
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E29.26
Forward P/E24.98
PEG ratio1.96
Price / sales—
Price / book6.29
EV / revenue9.65
EV / EBITDA23.81
Gross margin54.96%
Operating margin38.05%
Profit margin35.00%
Return on equity23.54%
Return on assets11.93%
Debt / equity9.77
Current ratio3.19
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $12.00B | $11.02B | $9.87B | $8.93B | +8.9% |
| Operating revenue | $11.97B | $11.02B | $9.87B | $8.93B | +8.6% |
| Cost of revenue | $1.65B | $1.53B | $1.26B | $1.08B | +7.9% |
| Gross profit | $10.35B | $9.49B | $8.61B | $7.85B | +9.1% |
| Research & development | $4.04B | $8.26B | $3.69B | $2.66B | -51.1% |
| Selling, general & admin | $1.75B | $1.46B | $1.14B | $944.70M | +19.7% |
| Total operating expense | $5.80B | $9.72B | $4.83B | $3.60B | -40.4% |
| Operating income | $4.55B | -$233.40M | $3.78B | $4.25B | +2,051.3% |
| Net interest income | $477.60M | $567.50M | $570.60M | $89.80M | -15.8% |
| Pre-tax income | $4.64B | $248.50M | $4.38B | $4.23B | +1,768.5% |
| Tax provision | $690.00M | $784.10M | $760.20M | $910.40M | -12.0% |
| Net income | $3.95B | -$535.60M | $3.62B | $3.32B | +838.1% |
| Net income to common | $3.95B | -$535.60M | $3.62B | $3.32B | +838.1% |
| Basic EPS | 15.46 | -2.08 | 14.05 | 12.97 | +843.3% |
| Diluted EPS | 15.32 | -2.08 | 13.89 | 12.82 | +836.5% |
| EBIT | $4.66B | $279.10M | $4.42B | $4.29B | +1,568.4% |
| EBITDA | $4.87B | $486.30M | $4.61B | $4.44B | +900.7% |
| Basic shares | 255.70M | 257.90M | 257.70M | 256.10M | -0.9% |
| Diluted shares | 258.00M | 257.90M | 260.50M | 259.10M | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $5.08B | $4.57B | $10.37B | $10.50B | +11.3% |
| Cash & short-term investments | $6.61B | $6.12B | $11.22B | $10.78B | +8.0% |
| Accounts receivable | $2.05B | $1.61B | $1.56B | $1.44B | +27.6% |
| Inventory | $1.69B | $1.21B | $738.80M | $460.60M | +39.9% |
| Total current assets | $11.20B | $9.60B | $14.14B | $13.23B | +16.7% |
| Property, plant & equipment | $3.08B | $2.58B | $1.45B | $1.46B | +19.3% |
| Goodwill & intangibles | $1.51B | $1.91B | $1.93B | $1.69B | -21.0% |
| Total assets | $25.64B | $22.53B | $22.73B | $18.15B | +13.8% |
| Total current liabilities | $3.86B | $3.56B | $3.55B | $2.74B | +8.3% |
| Total debt | $2.03B | $1.74B | $808.40M | $899.70M | +16.4% |
| Total liabilities | $6.98B | $6.12B | $5.15B | $4.24B | +13.9% |
| Retained earnings | $13.56B | $9.61B | $10.14B | $6.52B | +41.2% |
| Shareholder equity | $18.67B | $16.41B | $17.58B | $13.91B | +13.7% |
| Working capital | $7.34B | $6.03B | $10.60B | $10.49B | +21.7% |
| Net tangible assets | $17.15B | $14.50B | $15.65B | $12.22B | +18.3% |
| Shares issued | 253.99M | 256.94M | 257.70M | 257.01M | -1.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $3.95B | -$535.60M | $3.62B | $3.32B | +838.1% |
| Depreciation & amortisation | $209.80M | $207.20M | $181.30M | $148.30M | +1.3% |
| Stock-based compensation | $685.90M | $698.50M | $581.20M | $491.30M | -1.8% |
| Change in working capital | -$1.20B | -$514.80M | -$265.70M | $340.80M | -132.9% |
| Operating cash flow | $3.63B | -$492.60M | $3.54B | $4.13B | +837.2% |
| Capital expenditure | -$437.60M | -$485.40M | -$258.40M | -$204.70M | +9.8% |
| Investing cash flow | -$945.40M | -$3.77B | -$3.14B | -$321.10M | +74.9% |
| Share buybacks | -$2.39B | -$1.58B | -$653.70M | -$172.00M | -50.9% |
| Financing cash flow | -$2.26B | -$1.49B | -$562.20M | -$67.70M | -51.3% |
| Free cash flow | $3.19B | -$978.00M | $3.28B | $3.93B | +426.6% |
| End cash position | $5.09B | $4.57B | $10.37B | $10.51B | +11.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $3.33B | $2.99B | $3.19B | $3.08B | $2.96B | +11.6% |
| Operating revenue | $3.33B | $2.99B | $3.19B | $3.08B | $2.94B | +11.6% |
| Cost of revenue | $489.20M | $392.80M | $466.00M | $414.80M | $407.50M | +24.5% |
| Gross profit | $2.84B | $2.59B | $2.72B | $2.66B | $2.56B | +9.7% |
| Research & development | $993.80M | $961.60M | $1.11B | $977.70M | $978.40M | +3.3% |
| Selling, general & admin | $582.20M | $493.70M | $487.00M | $445.10M | $424.60M | +17.9% |
| Total operating expense | $1.58B | $1.46B | $1.59B | $1.42B | $1.40B | +8.3% |
| Operating income | $1.27B | $1.14B | $1.13B | $1.24B | $1.15B | +11.4% |
| Net interest income | $120.60M | $114.80M | $118.60M | $122.40M | $118.70M | +5.1% |
| Pre-tax income | $1.39B | $1.25B | $1.33B | $1.30B | $1.28B | +11.1% |
| Tax provision | $292.00M | $221.50M | $139.90M | $215.90M | $250.10M | +31.8% |
| Net income | $1.10B | $1.03B | $1.19B | $1.08B | $1.03B | +6.6% |
| Net income to common | $1.10B | $1.03B | $1.19B | $1.08B | $1.03B | +6.6% |
| Basic EPS | 4.34 | 4.06 | 4.69 | 4.24 | 4.02 | +6.9% |
| Diluted EPS | 4.31 | 4.02 | 4.65 | 4.20 | 3.99 | +7.2% |
| EBIT | $1.27B | $1.14B | $1.33B | $1.30B | $1.15B | +11.4% |
| EBITDA | $1.33B | $1.19B | $1.39B | $1.36B | $1.21B | +10.9% |
| Basic shares | 253.70M | 254.10M | 253.90M | 255.60M | 256.70M | -0.2% |
| Diluted shares | 255.20M | 256.30M | 256.10M | 257.60M | 258.90M | -0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.14B | $5.49B | $5.08B | $4.94B | $4.97B | +11.8% |
| Cash & short-term investments | $7.85B | $7.25B | $6.61B | $6.29B | $6.38B | +8.4% |
| Accounts receivable | $2.13B | $2.00B | $2.05B | $1.95B | $1.89B | +6.9% |
| Inventory | $1.77B | $1.77B | $1.69B | $1.63B | $1.50B | -0.1% |
| Total current assets | $12.54B | $11.73B | $11.20B | $10.57B | $10.43B | +6.9% |
| Property, plant & equipment | $3.33B | $3.29B | $3.08B | $3.02B | $2.65B | +1.0% |
| Goodwill & intangibles | $1.50B | $1.51B | $1.51B | $1.52B | $1.52B | -0.4% |
| Total assets | $27.42B | $26.48B | $25.64B | $24.86B | $24.04B | +3.5% |
| Total current liabilities | $3.94B | $3.88B | $3.86B | $4.48B | $4.14B | +1.5% |
| Total debt | $1.98B | $1.99B | $2.03B | $1.83B | $1.53B | -0.4% |
| Total liabilities | $7.18B | $7.12B | $6.98B | $7.54B | $6.86B | +0.7% |
| Retained earnings | $15.69B | $14.59B | $13.56B | $12.37B | $11.29B | +7.5% |
| Shareholder equity | $20.25B | $19.36B | $18.67B | $17.32B | $17.18B | +4.6% |
| Working capital | $8.61B | $7.85B | $7.34B | $6.09B | $6.29B | +9.6% |
| Net tangible assets | $18.75B | $17.86B | $17.15B | $15.80B | $15.65B | +5.0% |
| Shares issued | 253.35M | 254.16M | 253.99M | 253.95M | 256.29M | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.10B | $1.03B | $1.19B | $1.08B | $1.03B | +6.6% |
| Depreciation & amortisation | $56.50M | $55.90M | $55.70M | $54.00M | $51.70M | +1.1% |
| Stock-based compensation | $170.20M | $166.40M | $157.60M | $194.90M | $167.30M | +2.3% |
| Change in working capital | -$115.00M | $244.70M | -$947.80M | $149.60M | -$132.40M | -147.0% |
| Operating cash flow | $1.13B | $1.43B | $498.00M | $1.24B | $1.07B | -21.2% |
| Capital expenditure | -$112.20M | -$133.40M | -$149.40M | -$101.80M | -$145.70M | +15.9% |
| Investing cash flow | -$45.80M | -$431.90M | -$288.10M | -$117.00M | -$484.50M | +89.4% |
| Share buybacks | -$473.80M | -$565.40M | -$130.90M | -$1.16B | -$397.70M | +16.2% |
| Financing cash flow | -$426.70M | -$538.80M | -$77.20M | -$1.15B | -$349.20M | +20.8% |
| Free cash flow | $1.01B | $1.29B | $348.60M | $1.14B | $927.40M | -21.7% |
| End cash position | $6.15B | $5.50B | $5.09B | $4.95B | $4.98B | +11.8% |
Options analytics
Put / call volume
1.66
Put-heavy session
Put / call open interest
1.76
Positioning, not flow
Max pain
520.00
+3.5% from spot
ATM implied vol
51.7%
Nearest strike to spot
Skew (10% OTM)
+24.4%
Puts bid over calls
Call volume
239
Contracts, this expiry
Put volume
396
Contracts, this expiry
Heaviest call OI
520.00
96 contracts
Heaviest put OI
460.00
166 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 4.75 | 4.73 | -0.3% |
| Mar 2026 | 4.31 | 4.47 | +3.8% |
| Dec 2025 | 5.15 | 5.03 | -2.3% |
| Sep 2025 | 4.58 | 4.80 | +4.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.22 | 12 | $3.41B | +11.0% |
| Next quarter | 4.56 | 13 | $3.53B | +10.5% |
| Current year | 16.17 | 15 | $13.25B | +10.4% |
| Next year | 20.11 | 15 | $14.55B | +9.8% |
Analyst targets & ownership
Mean target$571.39
High target$672.00
Low target$350.00
Implied upside13.03%
Analyst count28
ConsensusBUY
Strong buy / Buy6 / 20
Hold5
Sell / Strong sell1 / 0
Held by insiders0.21%
Held by institutions97.93%
Institutions holding2.43K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
515.94
-2.02% from price
SMA 20
515.42
-2.54% from price
SMA 50
519.19
-3.25% from price
SMA 100
492.00
+2.75% from price
SMA 200
474.12
+5.94% from price
EMA 12
513.45
-1.54% from price
EMA 26
517.63
-2.34% from price
EMA 50
513.57
-1.56% from price
RSI (14)
37.7
Neutral
MACD (12,26,9)
-4.18
Hist -2.32
ATR (14)
11.85
2.36% of price
Realised vol 30D
18.5%
Annualised
Bollinger upper
530.45
20, 2σ
Bollinger lower
500.38
20, 2σ
50 / 200 cross
Golden
519.19 vs 474.12
Trend bias
Above 200
+5.94%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.50
Less volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
18.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-15.2%
Peak to trough
Max drawdown 5Y
-29.1%
Peak to trough
ATR 14
11.85
2.36% of price
Beta (reported)
0.28
5Y monthly, from filing
Short interest
Shares short
4.72M
Prior 4.15M
Change vs prior
+13.7%
Shorts adding
% of float
2.10%
Normal
% of shares out
1.86%
Against total outstanding
Days to cover
4.7
Liquid
Float
252.69M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 28, 26 | UBS | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 4, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 4, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Aug 4, 26 | Canaccord Genuity | MAINTAINED | Hold | Hold |
| Jul 13, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 7, 26 | Baird | MAINTAINED | Underperform | Underperform |
| May 6, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| May 5, 26 | Canaccord Genuity | MAINTAINED | Hold | Hold |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split2:1
Split dateAug 24, 2000
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-01
Periodic Financial Reports
10-Q · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-07-07
Offering Registrations
S-8 POS · 2026-05-13
Periodic Financial Reports
10-Q · 2026-05-05
Corporate Changes & Voting Matters
8-K · 2026-05-04
Proxy Statements
DEFA14A · 2026-04-29
Headlines
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Zacks · 21h ago
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Zacks · 2d ago
Vortex Energy Commissions Hydrogen and Helium Study at Robinsons River Salt Project
GlobeNewswire · 2d ago
2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down
StockStory · 2d ago
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Motley Fool · 3d ago
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
Insider Monkey · 4d ago
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
Simply Wall St. · 5d ago
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Zacks · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.